

Towards an equitable, predictable & sustainable pharma market in Greece



Labrina Barmpetaki

President, PhARMA Innovation Forum Greece

Managing Director, AbbVie Greece, Cyprus & Malta

Significant footprint of the 26 innovative PIF companies in Greece

Innovation equals value for the patient & the economy

46%

Funding of the total pharma budget (2022)

> 55% of 2021 clawback allocated to PIF companies

€ 1,3 billion in mandatory paybacks (in 2021)

4.100

Direct jobs

47% women (35% in top & middle management / 31% in CEO positions)

4 PIF employees generate +1 in the pharma ecosystem

> 90.000

patients in 520 support programs (2019-2021)

290 patient awareness campaigns in 130 therapeutic areas

740 CSR & 100 environmental programs

90

innovative medicines coming in next 2 years

Growing R&D investment: (2021 vs 2019)

+23% Clinical Trials

+32% patients enrolled

+28% centers / investigators

Key priorities for a sustainable pharmaceutical market

Equity - Predictability - Sustainability

Mandatory paybacks

- Unsustainable situation (~70% paybacks for innovation)
- Target: control the growth & gradual decline of paybacks
- Clawback cap max 30%


Funding of innovation

- GDP growth ↔ pharma budget
- RRF
- Unified budget
- Additional funding & reforms (e.g., uninsured, sin taxes)
- Incentives for innovation

Structural reforms

- Short – term
- Medium-long term

Where should we focus?



- ✓ Informed policy decisions
- ✓ Institutional dialogue
- ✓ Open communication
- ✓ Transparency & Trust



IF NOT US,
WHO?
IF NOT NOW,
WHEN?

JOHN F. KENNEDY

*Thank
you*

